Thus, we hypothesize that combinations of CXCL14 with the HPV vaccines will further augment antitumor responses by enhancing T-cell infiltration and MHC-I antigen presentation, leading to robust tumor suppression [41,42]. The gene discussed is CXCL14; the disease is neoplasm.